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Treatment of Vitiligo Vulgaris with Narrow Band UVB (311nm)
for One Year and the Effect of Addition of Folic Acid and
Vitamin B12
M. TJIOE1 , M. J .P. GERRITSEN1 , L. JUHLIN2 and P. C. M. VAN DE KERKHOF1
Department of Dermatology, 1University Medical Center Nijmegen, The Netherlands and 2University Hospital Uppsala, Sweden
Narrow band UVB is succeeding psoralen and UVA possibilities. Narrow band UVB in particular has been
a major breakthrough and is superseding PUVA as theirradiation as the main treatment of vitiligo vulgaris in
several European countries. Vitamin B12 and folic acid main treatment in several countries (7, 8). So far,
however, controlled studies on the eYcacy of narrowde ciency in some vitiligo patients has prompted research-
ers to investigate the eYcacy of these vitamins in the band UVB are not available. It should be taken into
consideration that only UVB therapy is eVective aftertreatment of vitiligo. In the present controlled study we
investigated the value of narrow band UVB phototherapy prolonged treatment and that long-term, placebo-
controlled studies for approaches where ample evidencein the treatment of vitiligo and the possible additive eVect
of vitamin B12 and folic acid. Twenty-seven patients with is available are diYcult to justify. In order to further
substantiate the evidence for the eYcacy of long-termlong-term stable vitiligo were included and randomized in
a ‘‘UVB only’’ (UVB) or ‘‘UVB combined with vitamin narrow band UVB therapy, it is important to study
patients with long-standing stable vitiligo.B12 and folic acid’’ (UVB+ ) group. Patients were irradi-
ated thrice weekly for one year, whilst repigmentation Research on the aetiology and pathomechanisms of
vitiligo has provided some insight into the biochemicalwas carefully monitored. In 92% (25/27) of the patients
up to 100% repigmentation was seen. Repigmentation was pathways involved. This has resulted in the development
of phototherapy treatments combined with several bio-notable in lesions on the face, neck and throat, lower arm,
chest, back and lower legs, whilst repigmentation on the chemical compounds such as pseudocatalase, calcium
chloride and phenylalanine (9–14).hands, wrists, feet and ankles proved to be minimal.
Maximum repigmentation rates did not diVer signi cantly It has been suggested that vitamin B12 and folic acid
may play a role in the melanin synthesis pathway, asbetween the UVB group and the UVB + group. Our study
recon rms that narrow band UVB phototherapy is an the pteridine part of folic acid and N-N-methylene
tetrahydrofolate as well as the vitamin B12-dependenteVective treatment for vitiligo and shows that co-treatment
with vitamin B12 and folic acid does not improve the formation of methionine could interfere with processes
leading to depigmentation and pigmentary dilutionoutcome of treatment of vitiligo with narrow band UVB
phototherapy. Key words: repigmentation; therapy; (15–17). Several reports suggest that a de ciency of
vitamin B12 and folic acid could be a common character-melanin; phototherapy .
istic of vitiligo, while others contradict this supposition(Accepted May 14, 2002.)
(18–20). Therefore it is tempting to hypothesize that
Acta Derm Venereol 2002; 82: 369–372. vitamin B12 and folic acid may contribute to the eYcacy
of phototherapy in vitiligo.Milan Tjioe, Department of Dermatology, University
The aim of the present study is to con rm theMedical Center Nijmegen, P.O.Box 9101, NL-
therapeutic value of narrow band UVB in the treatment6500 HB Nijmegen, The Netherlands. E-mail:
of patients with stable vitiligo and, secondly, to evaluateM.Tjioe@derma.azn.nl
the additional eVect of vitamin B12 and folic acid on
the treatment of vitiligo vulgaris with narrow band UVB
phototherapy using a non-blinded approach comparingVitiligo has been known for centuries and is a disease
UVB and vitamin B12 and folic acid with narrowcharacterized by the appearance of white patches, due
band UVB.to a loss of melanocytes (1–3). Although several treat-
ments have been suggested in past years, it was not until
MATERIAL AND METHODSthe 1900s that the  rst eVective treatment, photochemo-
therapy, was found (4–6). Psoralen and UVA irradiation
Patients(PUVA) treatment has been the only successful treat-
ment for decades and in some countries PUVA is still Twenty-seven patients (male and female) aged 18 and above,
the main treatment for generalized vitiligo. Recently, with stable vitiligo vulgaris (at least one year no changes) and
Fitzpatrick’s skin type II–IV from our outpatient clinic wereadvances in phototherapy have provided new treatment
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Table II. Percentage of repigmentation in diVerent body areasincluded in the study, after written informed consent had been
obtained. Patients using any medical treatment for their vitiligo of all the patients (n =27)
at the time of the study were excluded. Other exclusion criteria
were patients with a history of skin cancer or dysplastic naevus Area No. of Repigmentation Repigmentation
patients (%) Mean ± SD Median (range)syndrome, photosensitivity or using photosensitizing medi-
cines, psychiatric or epileptic disorders, known renal failure
and known allergies to substances in the trial medication. The Face 19 71.8 ± 35.5 90 (5–100)
Neck/Throat 7 68.6 ± 40.7 90 (5–100 )demographic data of the patients are shown in Table I.
Upper Arm 4 65.0 ± 31.0 65 (30–100)
Elbow 12 50.4 ± 29.8 45 (10–100)Treatments
Lower Arm 7 80.0 ± 24.5 90 (30–100)
Hand/Wrist 18 35.6 ± 31.5 22.5 (10–100)The patients were randomized in 2 narrow band UVB treat-
Axilla 17 37.4 ± 31.9 40 (0–100 )ment groups. The  rst group received only narrow band UVB
Chest 9 71.1 ± 35.9 90 (20–100)phototherapy, the second group received twice daily vitamin
Abdomen 3 80.0 ± 10.0 80 (70–90)B12 (cobalamin) 1,000 mg sustained release tablets (Orthica
Back 10 84.0 ± 27.5 92.5 (10–100)B.V., Weesp, The Netherlands) and folic acid 5mg tablets
Groin 14 70.4 ± 25.5 77.5 (20–100)(Dumex, The Netherlands). These doses were chosen in con-
Upper Leg 6 55.0 ± 40.9 70 (0–100)cordance with a previous study by Juhlin & Olsson (21). Both
Knee 5 62.0 ± 41.5 80 (0–100 )groups were irradiated with narrow band (311 nm) UVB,
Lower Leg 12 85.0 ± 16.1 90 (60–100)as generated by Philips TL-01 lamps in a Waldmann 7001
Foot/Ankle 12 12.1 ± 10.8 10 (0–40)cabin (Waldmann Medical Technology, The Netherlands).
Irradiation was given 3 times a week for 12 months and started
with 0.10 J/cm2 exposure, which increased by 0–30% every
arm, chest, back and lower legs, while less than 25%next visit on an individual basis.
All the vitiliginous areas were carefully monitored monthly repigmentation (median values) was seen on the hands,
during the study period, including before and after photo- wrists, feet and ankles.
graphs. The percentage of repigmentation was visually estim- The maximum repigmentation in vitiliginous lesions
ated in all areas. As a primary eYcacy criterion we selected
for both groups is shown in Fig. 1. No signi cantthe areas showing the most active repigmentation. This was
diVerence in repigmentation was reached at any of thedesignated as ‘‘maximum repigmentation’’.
Treatment was continued for one year after start of photo- monthly measurement points between the 2 groups
therapy or discontinued earlier if full repigmentation was (p ³ 0.175). No additional eVect of vitamin B12 and
reached before that time. folic acid on repigmentation was seen on less responsive
Treatment outcome was visually scored as the percentage
areas such as either the hands or feet (p ³ 0.23).of repigmentation of depigmented lesions.
Statistical analysis was performed with a one-way ANOVA
test, on SPSS 7.5 for Windows.
RESULTS
The mean cumulative dose of narrow band UVB
given to each patient was 126.7 ± 88.6 J/cm2 (11.6–401.8
J/cm2), both groups taken together (Table I ). Twenty-
 ve of the 27 patients showed prominent repigmentation
on most lesions of the body. In each group, one patient
showed less than 5% repigmentation after 4 months of
phototherapy and these patients were advised to discon-
tinue phototherapy treatment.
As shown in Table II, ³ 90% repigmentation (median Fig. 1. Course of maximum repigmentation during one year narrow
band UVB phototherapy with ( m ) or without ( d ) medication.values) was reached on the face, neck and throat, lower
Table I. Patient characteristics
Characteristics Control group (UVB) Vitamin group (UVB+ )
No. of patients 13 14
Skin type II 5 3
Skin type III 7 10
Skin type IV 1 1
Age mean ± SD (range) 41.6 ± 8.7 (20–51) 46.8 ± 10.2 (29–68)
Sex, M/F 6/7 5/9
Duration of disease mean ± SD (range) 10.8 ± 9.9 (1–30) 18.3 ± 13.1 (1–47)
Percentage of body surface aVected mean ± SD (range) 8.4 ± 5.6 (2–18) 10 ± 7.5 (3–26)
Mean cumulative dose narrow band UVB ± SD (range) 128.25 ± 109.57 (18.8–401.73) 125.11 ± 66.57 (11.09–214.24 )
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An example of an average response in a patient
treated with UVB phototherapy alone is presented in
Fig. 2. In all patients transient erythema was observed
occasionally, usually experienced as localized prickling
of the skin within 24 h of irradiation. However, these
responses were mild and never induced aggravation of
the lesions (Koebner phenomenon).
DISCUSSION
So far, no standardized scoring method for evaluating
the eVect of repigmentation therapies is available. A
Psoriasis Area Severity Index (PASI )-type score, such
as is used for psoriasis, would be a great step forward
to evaluate and compare the eVect of repigmentation
between diVerent therapies. Some studies use a rather
inaccurate graded scoring method ( less than 30%,
30–70% and more than 70% repigmentation, or total,
partial and no repigmentation) (7, 22–25). Our study
shows that only slight repigmentation or no repigmenta-
tion at all was seen on the dorsa of the hands, feet and
the inner wrist, while other areas such as the face, chest,
extensor surfaces of the lower arm and leg, back and
neck/throat often repigmented readily and completely
(Fig. 2 and Table II ). Previously, resistance of the hands,
feet and the inner wrist has been suggested for PUVA
phototherapy, although this study did not provide a
systematic quantitative analysis (25). On the other hand,
some studies claim to achieve full repigmentation, again
not specifying the responses per body region (10).
In view of the substantial intra-individual variability,
we have avoided the pitfall of a general score and
instead opted for the approach of scoring repigmenta-
tion visually per lesion and retrospectively selecting the
maximum repigmented area in each patient as the prim-
ary eYcacy criterion. As an additional eYcacy criterion,
we used the repigmentation in all body areas. A modi ed
PASI score, with special attention to less responsive
areas, possibly assisted by computerized measurement
of the total reduction in vitiliginous areas could
have provided more insight into the eYcacy of vitiligo
treatments.
Although no large studies and no controlled studies
have been done, narrow band UVB has been proven in
some studies to be eVective in inducing repigmentation
in patients with vitiligo (8, 23, 26). Our study shows
that narrow band UVB treatment results in an up to
100% repigmentation of depigmented lesions in 92%
(25/27) of patients with long-term stable vitiligo vul-
garis. During this treatment period no relapse was seen
and apart from some prickling sensations, usually on
Fig. 2. Before (a) and after (b) photographs of a vitiliginous area on
the lower legs and feet of a patient. Note the minimal repigmentation
on the feet and ankles. Patient was treated with narrow band UVB
alone. Photographs were taken after an interval of 12 months.
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ation therapy. J Am Acad Dermatol 2000; 42: 245–253.
seen. 9. Schallreuter KU, Wood JM, Berger J. Low catalase levels
It has been reported that folic acid and vitamin in the epidermis of patients with vitiligo [see comments].
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formation. Physiol Rev 1950; 30: 91–126.
The present study recon rmed the eYcacy of narrow 16. Schallreuter KU, Wood JM, Pittelkow MR, Gutlich M,
band UVB phototherapy in vitiligo but did not show Lemke KR, Rodl W, et al. Regulation of melanin biosyn-
thesis in the human epidermis by tetrahydrobiopterin.any advantage from adding vitamin B12 and folic acid.
Science 1994; 263: 1444–1446.A possible explanation for the discrepancy between
17. Schallreuter KU, Wood JM, Ziegler I, Lemke KR,the studies could be that we used an optimal dose of
Pittelkow MR, Lindsey NJ, et al. Defective tetrahydrobi-
narrow band UVB for a long period of time, which, opterin and catecholamine biosynthesis in the depigmenta-
owing to its high eYcacy, hides any eVect of vitamin tion disorder vitiligo. Biochim Biophys Acta 1994; 1226:
181–192.B12 and folic acid, which are thus not needed.
18. Banerjee AK, Banerjee DK, Chaudhury DS. Serum vit-
amin B12 level in vitiligo – a preliminary study. Bull
Calcutta Sch Trop Med 1970; 18: 73–75.ACKNOWLEDGEMENT
19. Kim SM, Kim YK, Hann SK. Serum levels of folic acid
We express our thanks to Orthica B.V. for supplying the and vitamin B12 in Korean patients with vitiligo. Yonsei
vitamin B12 tablets. Med J 1999; 40: 195–198.
20. Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid
and vitamin B12 in vitiligo: a nutritional approach. Cutis
1992; 50: 39–42.REFERENCES
21. Juhlin L, Olsson MJ. Improvement of vitiligo after oral
treatment with vitamin B12 and folic acid and the1. Hann SK, Chung HS. historic view of vitiligo in Korea.
Int J Dermatol 1997; 36: 313–315. importance of sun exposure. Acta Derm Venereol 1997;
77: 460–462.2. Lee S. Vitiligo auf ein historischen Portra¨t. Hautarzt 1982;
33: 335–336. 22. Kim HY, Kang KY. Epidermal grafts for treatment of
stable and progressive vitiligo. J Am Acad Dermatol 1999;3. Singh G, Ansari Z, Dwivedi RN. Letter: vitiligo in ancient
Indian medicine. Arch Dermatol 1974; 109: 913. 40: 412–417.
23. Nieuweboer-Krobotova L, Westerhof W. Treatment of4. Benedetto AV. The psoralens. An historical perspective.
Cutis 1977; 20: 469–471. vitiligo with UVB (311 nm) vs topical PUVA. Ned Tijdschr
Derm Ven 1997; 7: 95–97.5. Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko
C, et al. Psoralen photobiology and photochemotherapy: 24. Orecchia G, Perfetti L. Photochemotherapy with topical
khellin and sunlight in vitiligo. Dermatology 1992; 184:50 years of science and medicine. J Dermatol Sci 1999;
19: 78–88. 120–123.
25. Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo6. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin
Dermatol 1997; 15: 921–926. with khellin and ultraviolet A [see comments]. J Am Acad
Dermatol 1988; 18: 693–701.7. Westerhof W, Nieuweboer-Krobotova L. Treatment of
vitiligo with UV-B radiation vs topical psoralen plus 26. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet
B is a useful and well-tolerated treatment for vitiligo. JUV-A [see comments]. Arch Dermatol 1997; 133:
1525–1528. Am Acad Dermatol 2001; 44: 999–1003.
Acta Derm Venereol 82
